As the world marks the International Childhood Cancer Day (ICCD) today, childhood cancer survivors, families, and experts have called on the federal ...

Leukemia is a leading cause of death among children in India, with over 30,000 cases diagnosed annually. Early diagnosis is ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in allogeneic CAR T therapies currently valued at approximately $299 million, has published new data ...

Q4 2024 Management View CEO Paul Stoffels highlighted 2024 as a pivotal year for Galapagos, emphasizing the FDA IND clearance for GLPG5101 and strong results from the ATALANTA study in non-Hodgkin ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

When a tumor develops, it creates a structure around itself called the tumor stroma, within which blood and lymphatic vessels ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...